Trials / Completed
CompletedNCT01128855
A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects
A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Subcutaneous Injections of GSK2402968 in Non-ambulant Subjects With Duchenne Muscular Dystrophy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is investigate the pharmacokinetics, safety and tolerability of single subcutaneous administration of GSK2402968 in non-ambulant boys with Duchenne muscular dystrophy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 3 mg/kg GSK2402968 | Weekly subcutaneous injection |
| DRUG | 6 mg/kg GSK2402968 | Weekly subcutaneous injection |
| DRUG | 9 mg/kg GSK2402968 | Weekly subcutaneous injection |
| DRUG | 12 mg/kg GSK2402968 | Weekly subcutaneous injection |
| OTHER | Placebo | Weekly Placebo |
Timeline
- Start date
- 2010-07-12
- Primary completion
- 2011-10-25
- Completion
- 2011-10-25
- First posted
- 2010-05-24
- Last updated
- 2017-07-18
Locations
2 sites across 2 countries: United States, France
Source: ClinicalTrials.gov record NCT01128855. Inclusion in this directory is not an endorsement.